Aberrantly Activated APOBEC3B Is Associated With Mutant p53-Driven Refractory/Relapsed Diffuse Large B-Cell Lymphoma

Tumor protein 53 ( ) mutation predicts an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL), but the molecular basis for this association remains unclear. In several malignancies, the cytidine deaminase apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) has been report...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Frontiers in immunology 2022-05, Vol.13, p.888250-888250
Hauptverfasser: Zhang, Xuzhao, Wu, Zhaoxing, Hao, Yuanyuan, Yu, Teng, Li, Xian, Liang, Yun, Li, Jinfan, Huang, Liansheng, Xu, Yang, Li, Xiuzhen, Xu, Xiaohua, Wang, Weiqin, Xu, Genbo, Zhang, Xiaohong, Lv, Qinghua, Fang, Yongming, Xu, Rongzhen, Qian, Wenbin
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
Beschreibung
Zusammenfassung:Tumor protein 53 ( ) mutation predicts an unfavorable prognosis in diffuse large B-cell lymphoma (DLBCL), but the molecular basis for this association remains unclear. In several malignancies, the cytidine deaminase apolipoprotein B mRNA editing enzyme catalytic subunit 3B (APOBEC3B) has been reported to be associated with the G/C-to-A/T mutation. Here, we show that the frequency of this mutation was significantly higher in relapsed/refractory (R/R) than in non-R/R DLBCL, which was positively associated with the expression level. APOBEC3B overexpression induced the G/C-to-A/T mutation , resulting in a phenotype similar to that of DLBCL specimens. Additionally, APOBEC3B-induced p53 mutants promoted the growth of DLBCL cells and enhanced drug resistance. These results suggest that APOBEC3B is a critical factor in mutant p53-driven R/R DLBCL and is therefore a potential therapeutic target.
ISSN:1664-3224
1664-3224
DOI:10.3389/fimmu.2022.888250